Advertisement

Topics

Helsinn Group and DARA BioSciences, Inc. Company Profile

16:16 EDT 21st June 2018 | BioPortfolio

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.


News Articles [1098 Associated News Articles listed on BioPortfolio]

BRIEF—Helsinn Therapeutics appoints new chief executive

Switzerland’s Helsinn Group has appointed Paul Rittman as chief executive of its US subsidiary Helsinn…

Press Release: Helsinn Group and MEI Pharma -2-

Press Release: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatmen...

Helsinn obtains orphan designation for pracinostat to treat AML

Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have obtained orphan drug designation from the European Medicines Agency...Read More... The post Helsinn obtains orphan designa...

Helsinn Group to buy worldwide rights of Valchlor/Ledaga from Actelion Pharmaceuticals

Helsinn, a Swiss pharmaceutical group entered into a definitive agreement to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent for the topical treatment o...

Swiss pharma group invests millions to safeguard supply chain and regulatory compliance

Swiss pharmaceutical group, Helsinn, has revealed it will be investing €6 million at its drug product supply centre (Helsinn Birex Pharmaceuticals — HBP) in Dublin, Ireland, to safeguard its suppl...

Helsinn gets global Valchlor/Ledaga rights from Actelion

Johnson & Johnson division Actelion Pharmaceuticals Ltd. granted Helsinn Group global rights to market the topical skin cancer drug Valchlor/Ledaga (mechlorethamine). Financial terms were not disclose...

Pawar Law Group: Solid Biosciences Inc. Reminder: Important May 29, 2018 Lead Plaintiff Deadline in Class Action - SLDB

NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Pawar Law Group reminds shareholders who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences' initial public offering on...

Helsinn and Eisai take Aloxi patent fight all the way to US Supreme Court

After a US appeals court last year ruled against Helsinn Healthcare in its patent dispute with Israel’s…

Drugs and Medications [57 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [1876 Associated PubMed Articles listed on BioPortfolio]

Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area.

Combination therapies such as Dara-Rd and Dara-Vd show significantly higher survival rates after 12 months than the respective therapies without Daratumumab. The initial infusion of Daratumumab is ass...

Final size of a multi-group SIR epidemic model: Irreducible and non-irreducible modes of transmission.

A model of an epidemic outbreak incorporating multiple subgroups of susceptible and infected individuals is investigated. The asymptotic behavior of the model is analyzed and it is proved that the inf...

Introduction.

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

Front cover.

Clinical Trials [3715 Associated Clinical Trials listed on BioPortfolio]

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (...

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the combination regimen of daratumumab plus durvalumab (D2). The study will consist of 2 parts; Part...

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyc...

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethas...

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the tolerability and safety of subcutaneous (SC) delivery of co-formulated daratumumab and rHuPH20 preparation (DARA SC) in Japanese participants w...

Companies [1965 Associated Companies listed on BioPortfolio]

Helsinn Group and DARA BioSciences, Inc.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business mo...

DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through...

Helsinn Healthcare SA

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's unique business model is focused on the licensing of phar...

HELSINN HEALTHCARE S.A.

Helsinn's strategy is focused on three activities Integrated Licensing Helsinn uses an innovative approach to develop and market new pharmaceutical products:INTEGRATED LICENSINGHelsinn adds scient...

DyoDelta Biosciences Ltd

DyoDelta Biosciences Ltd., is a London based company specialising in deals in the Pharma / Biotech sector.We provide best-practice in corporate transactions through our management and associates. DyoD...

More Information about "Helsinn Group and DARA BioSciences, Inc." on BioPortfolio

We have published hundreds of Helsinn Group and DARA BioSciences, Inc. news stories on BioPortfolio along with dozens of Helsinn Group and DARA BioSciences, Inc. Clinical Trials and PubMed Articles about Helsinn Group and DARA BioSciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Helsinn Group and DARA BioSciences, Inc. Companies in our database. You can also find out about relevant Helsinn Group and DARA BioSciences, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record